Phase 1 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 19 years or older at the time of signing the consent form
- People who have at least one tumour that can be measured using standard imaging guidelines (called RECIST v1.1)
- People whose general physical functioning meets a specific standard (ECOG score of 0 or 1, meaning fully active or able to carry out light activities — confirm with trial site)
- People with a life expectancy of at least 12 weeks
- People whose blood test results show that their liver, kidneys, and blood cell counts are within acceptable ranges
- People who voluntarily sign a written consent form agreeing to take part in the study
- People whose cancer has been confirmed by laboratory testing of tissue or cell samples, and whose tumour cannot be removed by surgery and has reached an advanced stage
- People whose cancer carries a mutation in the BRCA1 or BRCA2 gene
Who may not be able to join:
- People with a history of a significant medical illness (confirm with trial site for specifics)
- People whose heart's electrical activity shows a prolonged QT interval — greater than 450 ms for men or greater than 460 ms for women — on a heart tracing test
- People who are still experiencing side effects from a previous cancer treatment that have not yet resolved
- People considered likely to have a serious allergic reaction to any ingredient in the study drug
- People who have previously taken part in another clinical trial and received an investigational drug or medical device as part of that trial
- People the trial investigator considers unsuitable for participation for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82 31 757 220
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1: Incidence of dose limiting toxicities (DLT) of DM5167; Part 1 and Part 2: Treatment emergent adverse events (TEAE) and serious adverse events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.